- Moderna (NasdaqGS:MRNA) will present late breaking Phase 3 data on its mRNA-1010 flu vaccine and mRESVIA RSV vaccine at the 2026 European Society of Clinical Microbiology and Infectious Diseases Congress.
- Interim results show strong immune response in individuals who received repeat doses of these vaccines.
- The data set includes information on immune response and tolerability in revaccinated participants.
For Moderna, known widely for its COVID-19 vaccine, these new mRNA-1010 and mRESVIA readouts highlight its effort to build a broader respiratory vaccine portfolio. Investors tracking NasdaqGS:MRNA now have additional clinical information on non COVID programs, at a time when many vaccine makers are working to extend mRNA applications beyond the pandemic.
The presentation of late stage data at a major infectious disease congress provides another reference point on how Moderna’s pipeline is progressing in flu and RSV. As more details emerge, attention may focus on durability of immune response, safety in repeat dosing and how these candidates might fit into future seasonal vaccination schedules.
Stay updated on the most important news stories for Moderna by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Moderna.
See which insiders are buying and buying and selling Moderna following this latest news.
For investors, the new mRNA-1010 and mRESVIA data fits into a period where Moderna is working to show that its mRNA know-how can support a repeat-vaccination business beyond COVID-19. Strong immune responses in revaccinated individuals are important because flu and RSV shots are typically annual, and durability plus tolerability in repeat dosing are key for real-world uptake. These late-breaking presentations also extend a recent run of conference engagement, including the World Vaccine Congress and LNP Formulation Summit. This keeps Moderna in front of clinicians and potential partners at the same time that commentators have been highlighting regulatory developments and the company’s shifting perception at agencies such as the FDA. For existing shareholders who have watched the stock move on the Moderna 2.0 cancer story and legal settlements, respiratory vaccines remain a core part of the broader pipeline story alongside oncology. The new data points do not resolve questions about future revenue or earnings, but they give the market one more concrete readout to judge whether the non COVID portfolio is progressing in line with expectations.
How This Fits Into The Moderna Narrative
- The flu and RSV readouts support the narrative’s focus on an expanded mRNA pipeline across infectious diseases, showing additional late-stage data in respiratory vaccines.
- They also highlight that seasonal vaccines and repeat dosing remain central. This sits alongside narrative concerns that slowing vaccine sales and competition could pressure long-term revenue stability.
- The specific emphasis on revaccination and tolerability adds detail that is not fully captured by the higher level discussion of regulatory engagement and pipeline breadth in the narrative.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Moderna to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
- ⚠️ Analysts highlight that Moderna faces revenue volatility from seasonal respiratory vaccines, and these new data do not remove that exposure.
- ⚠️ Competitive pressure in flu and RSV from companies such as Pfizer and GSK could limit how much market share or pricing power Moderna can secure, even with strong immune responses.
- 🎁 Positive revaccination data support the case that Moderna’s mRNA platform can extend beyond COVID-19 into recurring respiratory vaccine use.
- 🎁 Continued late stage readouts and active regulatory engagement align with views that a broader pipeline across infectious diseases and oncology could diversify the business over time.
What To Watch Going Forward
From here, focus on the full data set from the ESCMID congress, especially any detail on durability of protection, safety in repeat dosing, and comparisons with existing flu and RSV options from peers like Pfizer and GSK. Also watch how frequently management highlights these respiratory programs alongside the Moderna 2.0 cancer-vaccine story in future conferences and earnings updates, as that will signal how important they are to the overall pipeline mix. Any future regulatory filings or guidance on potential product launches in flu and RSV will help investors judge how these results might translate into real-world uptake and revenue contribution.
To ensure you're always in the loop on how the latest news impacts the investment narrative for Moderna, head to the community page for Moderna to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com